CD40-Binding Peptides for Autoimmune Inflammation Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for autoimmune diseases and type 2 diabetes, particularly those targeting the CD40-CD154 dyad, suffer from severe side effects and inefficacy in modulating chronic inflammation, leading to tissue degeneration and organ dysfunction.
Innovation Solution
Development of therapeutically effective CD40-binding peptides, less than 25 amino acids in length, that inhibit the interaction between CD40 and CD154, thereby modulating immune cell function and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies targeting CD40-CD154 dyad are used to treat autoimmune diseases and type 2 diabetes, then immune response modulation is achieved, but severe side effects occur and therapeutic efficacy is insufficient
Solution Approach 1:
The patent extracts only the essential functional region of the CD154 protein (amino acids 139-165) to create a truncated peptide that retains CD40 binding capability while removing regions responsible for harmful effects. This selective extraction achieves therapeutic efficacy with reduced side effects
Solution Approach 2:
The patent employs short peptides (19-38 amino acids) instead of full-length proteins or monoclonal antibodies. These shorter peptides are easier to manufacture, have improved pharmacokinetic properties, and can be administered repeatedly with minimal immunogenicity, providing a cost-effective therapeutic alternative
2Reliability
If full-length CD154 protein or monoclonal antibodies are used to block CD40-CD154 interaction, then immune modulation is achieved, but manufacturing complexity and cost increase
Solution Approach 1:
The invention extracts the minimal functional sequence (amino acids 139-165 of human CD154) required for CD40 binding. This truncated peptide can be synthesized using standard peptide synthesis methods, dramatically simplifying manufacturing compared to producing full-length proteins or complex monoclonal antibodies
Solution Approach 2:
The patent changes the molecular size parameter by using short peptides (19-38 amino acids) instead of large proteins. This parameter change maintains biological activity while improving manufacturability, stability, and pharmacokinetic properties
3Object-affected harmful factors
If conventional anti-inflammatory therapies are used to treat chronic inflammation in autoimmune diseases, then inflammation is suppressed, but tissue degeneration and organ dysfunction occur
Solution Approach 1:
The patent uses a peptide intermediary that specifically blocks the CD40-CD154 interaction pathway without broadly suppressing the immune system. This targeted approach reduces pathogenic inflammation while preserving normal immune functions, preventing tissue degeneration that occurs with conventional broad-spectrum anti-inflammatory therapies
Solution Approach 2:
The invention applies local quality by targeting a specific molecular interaction (CD40-CD154) rather than globally suppressing inflammation. The peptide specifically binds to CD40 and blocks only the harmful autoimmune-mediated inflammation, allowing other protective immune functions to continue normally
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively reduce chronic inflammation, prevent and reverse type 2 diabetes, and minimize autoimmune disease severity by altering CD40 signaling, promoting normal immune function without significant side effects.
Implementation Method 1
the peptide is a CD40-binding peptide that inhibits the interaction of CD40 and CD154
Data Source
Figure 1~2B
Figure 3~4
Figure 5~6
AI summary
Methods and materials for preventing and modulating atherosclerosis. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and atherosclerosis. The use of such peptides in reducing atherosclerosis, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower LDL cholesterol. Methods and materials for detecting T-cells that express CD40 (Th40 cells). Methods and materials for preventing, modulating, reducing and/or reversing type 2 diabetes and auto-inflammatory disease. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and type 2 diabetes. The use of such peptides in reducing type 2 diabetes, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower IL2, INFy, and IL17a. The use of such peptides to increase glucose transport protein (GLUT4). Methods and materials for detecting T-cells that express CD40 (Th40 cells).